The Los Angeles Post
California & Local U.S. World Business Lifestyle
Today: January 30, 2025
Today: January 30, 2025

Exclusive-US FDA finds control lapses at Moderna manufacturing plant

FILE PHOTO: People pose with syringe with needle in front of displayed Moderna logo
April 26, 2024
Patrick Wingrove - Reuters

By Patrick Wingrove

(Reuters) - U.S. drug regulators in September found quality control lapses at Moderna’s main factory including with equipment used to manufacture drug substance for its COVID-19 vaccine, according to the report obtained by Reuters via a Freedom of Information Act request.

The Sept. 11-21 inspection by the U.S. Food and Drug Administration took place at Moderna’s facility in Norwood, Massachusetts, which is used to manufacture the company’s COVID shot Spikevax and an experimental mRNA cancer vaccine being developed with Merck & Co.

The FDA report noted five separate observations, including that Moderna had released eight batches of "drug substance" - the active ingredient used to make mRNA vaccines - that was produced with equipment that had failed the company's cleaning verification tests.

The FDA did not say in the report if those batches were released to the public but identified the drug substance involved as being for the COVID vaccine. The agency declined to comment on the report.

Moderna in a statement said: "Upon receipt of the FDA’s findings, Moderna immediately and comprehensively updated the specific procedures identified and is confident that the actions taken will be satisfactory to regulators."

The company described the inspection as routine and said the findings do not reflect any product quality or safety concerns, adding that its COVID-19 vaccines are safe and effective.

It said all product released by the company was tested and meets product specifications and international regulatory requirements.

Steven Lynn, a former head of the FDA's Office of Manufacturing and Product Quality who is now a regulatory compliance consultant, said using the drug substance in question was a serious matter but that it was unclear whether the batches were released to consumers.

The FDA also found in its report that Moderna did not have the right measures at its facility to ensure expired materials were not used to make vaccines and that airborne contaminates did not make it into any products.

Inspectors found more than 2,000 expired items in Moderna's warehouse and cold storage not held in a separate or defined location from other materials, according to the report. It also said it found materials were used beyond their expiration date.

“At face value, it appears multiple controls designed to prevent contamination were deficient,” said Lynn.

There is no evidence that compliance failures flagged in the report known as a Form 483 resulted in harm to people who took Moderna’s COVID shot, its only marketed product, or clinical trial participants for other mRNA vaccines the company is developing.

The FDA has not issued a recall of any Moderna vaccines, according to its recalls, market withdrawals, and safety alerts database.

A Form 483 is a type of agency report containing "observations" that FDA inspectors "deem to be objectionable."

In 2021, Japan suspended use of 1.63 million doses of Moderna’s COVID vaccine after contaminates were found in some vials produced by Rovi, a contract manufacturer based in Spain. No manufacturing problems have previously been reported in any of Moderna’s own facilities.

The drugmaker has also bought a manufacturing facility in Marlborough, Massachusetts, announced in May.

Moderna in September said it was in talks with its partners that fill vials and syringes with its COVID vaccine globally to downsize production and bring more manufacturing in-house as demand has waned.

The vaccine maker said it expects additional capacity from its new mRNA manufacturing facilities in the UK, Canada and Australia when completed in 2025.

(Reporting by Patrick Wingrove; editing by Caroline Humer and Bill Berkrot)

Related Articles

Dollar set to pounce on euro if ECB offers dovish guidance PGA Tour contemplates announcing fines as part of study into slow play Brazil central bank hikes rates by 100 bps, confirms same in March

Related

Asia|Business|Finance|Technology

SoftBank in talks to invest up to $25 billion into OpenAI, FT reports

Japan's SoftBank is in talks to invest as much as $25 billion into ChatGPT maker OpenAI, the Financial Times reported on Wednesday.

SoftBank in talks to invest up to $25 billion into OpenAI, FT reports
Asia|Business|Economy|Political|US|World

Japan, US planning meeting between PM Ishiba and President Trump on Feb 7, Asahi reports

Japan and the United States are in the final stage of planning for a meeting between Prime Minister Shigeru Ishiba and President Donald Trump in Washington on Feb. 7, the Asahi

Japan, US planning meeting between PM Ishiba and President Trump on Feb 7, Asahi reports
Business|Political|Technology|US

Meta to pay $25 million to settle Trump's 2021 lawsuit over suspended accounts

Meta Platforms on Wednesday said it has agreed to pay about $25 million to settle a lawsuit by President Donald Trump over the company's suspension of his accounts after the Jan. 6, 2021,

Meta to pay $25 million to settle Trump's 2021 lawsuit over suspended accounts
Business|Economy|Finance|Stock Markets|US

Fed rate actions in 2025 seen in a narrow band, Goldman Sachs CEO says

The Federal Reserve's future moves on interest rates in 2025 will be in a narrow range unless the trajectory of inflation changes, Goldman Sachs CEO David Solomon said in comments

Fed rate actions in 2025 seen in a narrow band, Goldman Sachs CEO says
Share This

Popular

Asia|Business|Economy|Finance|Science|Technology

How China’s DeepSeek app compares to ChatGPT

How China’s DeepSeek app compares to ChatGPT
Business|Economy|Finance|Political|US

Oil steady as markets await clarity on tariffs by Trump on Canada, Mexico

Oil steady as markets await clarity on tariffs by Trump on Canada, Mexico
Asia|Business|Finance|Stock Markets|Technology

Microsoft, Meta CEOs defend hefty AI spending after DeepSeek stuns tech world

Microsoft, Meta CEOs defend hefty AI spending after DeepSeek stuns tech world
Asia|Business|Economy|US

Nissan cuts shifts, offers employee buyouts at 3 US plants in bid to shed jobs

Nissan cuts shifts, offers employee buyouts at 3 US plants in bid to shed jobs